Phase 1b data from LAPNET-01 in locally advanced pancreatic ductal adenocarcinoma reported median progression-free survival of 10.85 months, median overall survival of 16.43 months, a confirmed objective response rate of 29% among 41 evaluable patients, and a 23% conversion-to-surgery rate on NP137 plus mFOLFIRINOX. In a predefined subgroup with high tumor expression of the netrin-1 receptor neogenin, median PFS reached 15.65 months, conversion-to-surgery was 40%, and 12‑month overall survival was 100% at data cut-off. Grade 3 or higher adverse events occurred in 37% and were broadly consistent with the chemotherapy backbone.
The core development is NP137, a first-in-class anti-netrin-1 monoclonal antibody, positioned to pharmacologically target EMT-associated resistance. The single-arm, multicenter study enrolled 43 patients with unresectable disease at baseline and dosed NP137 at 14 mg/kg every two weeks with mFOLFIRINOX for up to 12 cycles. Outcomes compared favorably to historical benchmarks from FOLFIRINOX alone in LAPC, including NEOPAN. The findings were published in Nature and featured at AACR. The company plans a randomized, potentially registrational, phase 2 study in first-line metastatic PDAC that will incorporate a neogenin IHC assay to validate the biomarker as a potential companion diagnostic, alongside regulatory interactions in the US and EU to define the path forward.
Strategically, this program doubles down on resistance biology rather than incremental cytotoxic intensification. The early signal supports a biomarker-enriched approach: neogenin emerged as a candidate predictor of benefit, offering a route to narrower, potentially higher-yield development with clearer effect sizes and trial efficiency. The pivot from LAPC to metastatic first-line broadens commercial relevance but trades a conversion-to-surgery readout for hard survival endpoints in a setting where demonstrating OS gains over FOLFIRINOX remains challenging. The single-arm origin of the data elevates the need for randomized confirmation and disciplined assay validation, including cutoffs, reproducibility, and tissue handling.
For sites and CROs, adding a q2w antibody infusion onto mFOLFIRINOX is operationally feasible but increases chair time, monitoring, and scheduling complexity; the reported safety comparability suggests layering may be manageable in high-volume GI centers. The neogenin assay is the operational hinge: PDAC often relies on small-core biopsies with limited tissue, creating risks around adequacy, central vs local testing, and turnaround time that could slow first-line starts and inflate screen-fail rates. Pathology standardization, controls, and training will be essential to keep timelines intact. Sponsors and vendors should plan for robust sample logistics and pre-screen infrastructure if enrichment is pursued.
Regulatory dynamics will center on evidentiary standards for a resistance-targeting agent and parallel CDx development. A randomized phase 2 could be considered pivotal if it demonstrates clinically meaningful, biomarker-driven benefit with a prespecified assay and prospectively defined cutoffs, but OS will likely be the decisive endpoint in the US. Assay prevalence will dictate sample size and feasibility; if neogenin-high frequency is modest, adaptive enrichment or a hierarchical all-comers design with biomarker stratification may be necessary. EU and US alignment on CDx requirements, including PMA timelines for an IHC assay, will be a pacing item.
Near term, the design of the metastatic trial—control regimen, powering for OS, enrichment versus stratification, central testing workflows, and geographic footprint—will signal regulatory intent and operational complexity. Watch for clarity on neogenin prevalence, analytical validation packages for the IHC, sustained safety under combination pressure, and whether a LAPC program advances in parallel to capitalize on surgery conversion as an intermediate outcome. Additional signals from hepatocellular carcinoma and head and neck programs will inform whether netrin-1 blockade generalizes beyond PDAC or remains a tumor- and biomarker-specific play.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
